Questcor Pharmaceuticals — Investor Presentation (February 2011)
31 slides from Questcor Pharmaceuticals's investor presentation, Feb 28, 2011
Slide 1: Questcor
(SW QUESTCOR’
Slide 2: March 2011
NASDAQ: QCOR March 2011 NASDAQ: QCOR March 2011
Slide 3: Safe Harbor Statement
3 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa
Slide 4: Questcor Overview
4 Questcor Overview A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions
Slide 5: Questcor Overview
5 Questcor Overview Flagship Product: • Profitable, cash flow positive, $127M in cash, debt-free • 19 approved indications Key Markets: • Multiple Sclerosis, Infantile Spasms, Nephrotic Syndrome • Combined markets opportunity exceeds $1.5 billion Strategy: • Grow Acthar sales in each key market Fina
Slide 6: History of Acthar
6 History of Acthar 1950 2000 2010 1952 First Approved 1968-1973 DESI Review Label Expands 1950 1978 MS Indication Added 2000 2001 Questcor Acquires Acthar 2010 Label Modernized 19 Indications 2007 Questcor Changes Strategy 2010
Slide 7: Significant Barriers to Entry
7 Significant Barriers to Entry
Slide 8: Questcor Growth Engine
8 Questcor Growth Engine Multiple Sclerosis (MS) Infantile Spasms (IS) Nephrotic Syndrome (NS) Multiple Sclerosis (MS) Infantile Spasms (IS) Nephrotic Syndrome (NS)
Slide 9: Large Market Opportunity
9 Large Market Opportunity ~$65M ~$40M ~$3M ~$5M *Represents estimated net sales market opportunity based on internal company estimates ** Represents approximate current net sales annualized run rate based on internal company estimates ~$65M ~$40M ~$3M ~$5M $1B+ MS Sales IS Sales NS Sales $500M to $
Slide 10: Acthar and MS
10 Acthar and MS Acthar when “Steroids are not suitable” *Based on prescription data • Neurodegenerative disorder • Acute treatment for relapses • Dosing period is 1-2 weeks* • $40K-$50K/Rx Acthar when “Steroids are not suitable”
Slide 11: MS Sales - Record of Consistent Growth
11 MS Sales - Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which
Slide 12: Multiple Sclerosis
12 Multiple Sclerosis *Data on this slide is based on US only. Based on internal company estimates. $500M to $2B+ Potential Market
Slide 13: MS Trends
13 • Q4-2010 results – Q4-10 new paid Rxs up 66% vs. Q409 – MS sales over 50% of QCOR sales – Over $65M annualized run rate – Approximately one in six Rxs is a repeat patient • Growing number of Acthar prescribers – But only ~400 out of 8,000 neurologists • Speakers bureau growing MS Trends • Q4-201
Slide 14: MS Sales Calls vs. Paid New Rxs
14 MS Sales Calls vs. Paid New Rxs *MS call data approximate
Slide 15: Sales Force Expansion
15 Sales Force Expansion • Doubled sales force: hiring/training Aug-Oct 2010 (38 to 77 sales reps) • Newly expanded sales force began call activity Nov 1 – Significant increase in MS-treating neurologists targeted for sales calls – Now also targeting child neurologists for IS sales calls • MS paid R
Slide 16: Infantile Spasms
16 • Devastating, refractory form of childhood epilepsy – Very poor developmental outcome if inadequately treated • Not responsive to standard anti-epileptic drugs • Ultra-rare orphan disorder – 1,500 to 2,000 patients annually • Typically occurs in children less than 2 years old • Characterized by
Slide 17: Acthar and IS
17 • Used by over half of child neurologists • FDA approval 10/15/10 – 7 year orphan exclusivity for IS indication • Crisis therapy • Treatment for 2-4 weeks* • In a randomized, single-blinded, controlled study, 87% of patients achieved overall response (no spasms and no hypsarrhythmia) at two weeks
Slide 18: IS Sales Plan
18 • Significant variability in quarterly prescriptions • Q4-2010 sales within historic range • Promotion effort began 11/1/10 • Potential to increase IS revenue – Acthar currently used to treat 30-50% of IS patients IS Sales Plan • Significant variability in quarterly prescriptions • Q4-2010 sales
Slide 19: Nephrotic Syndrome
19 • Characterized by excessive spilling of protein from the kidney into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Significant unmet need – Few treatment options Nephrotic Syndrome • Characterized by excessive spilling of protein from the kidney i
Slide 20: Acthar and NS
20 • FDA-approved on label indication for reduction of proteinuria in: – Idiopathic types of nephrotic syndrome • Idiopathic membranous nephropathy • Focal segmental glomerular sclerosis (FSGS) • IgA nephropathy – Lupus nephritis • Treatment for 4-6 months* • $150K-250K/Rx Acthar and NS *Based on pr
Slide 21: Proof of Concept Data
21 • Available November 2010 • Case series showed response from Acthar in refractory idiopathic membranous nephropathy (on-label) – 9 of 11 patients met response criteria • Positive signal received in diabetic nephropathy investigator initiated trial (not on-label) – 9 of 15 patients on Acthar met r
Slide 22: R&D Effort in NS
22 • Dose response trial for idiopathic membranous nephropathy (on-label) – $5-7M multi-center trial, n~100 – Reduction of proteinuria is endpoint • Presently designing a well controlled study in collaboration with FDA for diabetic nephropathy (off- label) – Proof-of-concept study with different dos
Slide 23: NS Business Plan
23 • Nov 2010 ASN meeting – First meeting with commercial team presence – Data presented via podium/posters – 30+ doctor advisory board meeting • Hired 5 reps to sell Acthar to nephrologists – Develop selling process and generate sales – Initiate sales efforts in early March 2011 – Expand sales forc
Slide 24: Immediate Acthar Growth Opportunities
24 • MS - Build on sales momentum, lots of market headroom • IS - Incremental market share growth • NS - Establish Acthar as a therapeutic alternative in this sizeable market Immediate Acthar Growth Opportunities * Represents estimated net sales market opportunity based on internal company estimates
Slide 25: Financials
25 Financials Profitable Debt Free Cash Flow Positive Profitable Debt Free Cash Flow Positive
Slide 26: 2010 Financial Results
26 2010 Financial Results Record Sales (up 30%) and Solid Earnings (EPS up 35%) Net Sales ($M) Gross Margin Operating Inc ($M) EPS $115.1 93% $53.8 $0.54 $ 92% $41.2 $0.40 2010 2009 88.3 Record Sales (up 30%) and Solid Earnings (EPS up 35%) Net Sales ($M) Gross Margin Operating Inc ($M) EPS $115.1 9
Slide 27: Questcor is Cash Flow Positive
27 Questcor is Cash Flow Positive Debt-free balance sheet Cash / ST Investment Accounts Receivable $127M* $17M 2/18/11 Debt-free balance sheet *After return of $67 million of cash to shareholders through share repurchases. Cash / ST Investment Accounts Receivable $127M* $17M
Slide 28: Go Forward Plan - Sell More Acthar
28 • Expanded sales force to pursue MS/IS • Dedicated pilot NS sales team starting March 2011 • Develop other markets for Acthar – Acthar is its own pipeline with 15 other on-label and many possible other therapeutic uses – Further defining and developing the unique characteristics of Acthar • No bu
Slide 29: Investment Highlights
29 • Questcor is streamlined, focused & profitable • Acthar has sustainable competitive advantages • Focus on substantial growth in MS sales • Recent IS approval/label modernization • Possible upside with NS • Market sizes have good growth potential • Cash flow positive/no debt Investment Highlights
Slide 30: March 2011
NASDAQ: QCOR March 2011 NASDAQ: QCOR March 2011
Slide 31: Questcor
(NW QUESTCOR’
Questcor Pharmaceuticals — Investor Presentation (February 2011) on 6ix